/OKYO
OKYO Stock - OKYO Pharma Limited
Healthcare|BiotechnologyNASDAQ
$2.03+8.56%
+$0.16 (+8.56%) • Dec 19
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.34
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OKYO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.01 – $2.05
TARGET (TP)$2.33
STOP LOSS$1.87
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.16
52W High$3.35
52W Low$0.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-2,563 | $-3,866 | $-3,797 | $-2,423 | $-13,086 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-7,188,875 | $-15,694,549 | $-13,087,270 | $-6,231,000 | $-4,133,349 |
| Net Income | $-4,706,292 | $-16,825,461 | $-13,272,000 | $-5,431,000 | $-3,354,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.12 | $-0.00 | $-0.60 | $-0.36 | $-0.32 |
Company Overview
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 146.3% Upside
Now
$5
Low
$5
Average
$5
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 8th 2025 | B. Riley Securities | Initiation | Buy | $5 |
Earnings History & Surprises
OKYOBeat Rate
0%
Last 1 quarters
Avg Surprise
-32.8%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$-0.07
Q3 2025
EPS Surprise History
Q1 22
No data
Q4 22
No data
Q1 23
No data
Q4 23
No data
Q2 24
No data
Q4 24
No data
Q1 25
No data
Q3 25
-32.8%
$-0.07vs$-0.05
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2026 | Aug 10, 2026 | — | — | — | — |
Q4 2025 | Dec 22, 2025 | — | — | — | — |
Q3 2025 | Jul 18, 2025 | $-0.05 | $-0.07 | -32.8% | ✗ MISS |
Q1 2025 | Jan 29, 2025 | — | $-0.08 | — | — |
Q4 2024 | Oct 2, 2024 | — | $-0.10 | — | — |
Q3 2024 | Aug 13, 2024 | — | — | — | — |
Q2 2024 | May 13, 2024 | — | $-0.30 | — | — |
Q1 2024 | Jan 9, 2024 | — | — | — | — |
Q4 2023 | Oct 1, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 15, 2023 | — | — | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 30, 2022 | — | — | — | — |
Q4 2022 | Oct 1, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.47 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.37 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.15 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.06 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.16 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.00 | — | — |
Latest News
OKYO Pharma Chairman Gabriele Cerrone Acquires 24,551 Shares
📈 PositiveBenzinga•Dec 15, 2025, 01:35 PM
OKYO Pharma Announces New Analyses Of Corneal Images From Placebo-Controlled, Randomized, Double-Masked, Phase 2 Clinical Trial Of Urcosimod In Neuropathic Corneal Pain
📈 PositiveBenzinga•Dec 11, 2025, 01:38 PM
B. Riley Securities Initiates Coverage On OKYO Pharma with Buy Rating, Announces Price Target of $5
📈 PositiveBenzinga•Dec 8, 2025, 01:59 PM
OKYO Pharma Chairman And Founder Entity Panetta Partners Acquires 27,051 Ordinary Shares On NASDAQ And Lifts Holding To 10,491,746 Shares
📈 PositiveBenzinga•Dec 3, 2025, 12:13 PM
OKYO Pharma Says Executive Chairman Gabriele Cerrone Acquires 210K Of Company Shares On NASDAQ; Now Holds 10.38M Shares
📈 PositiveBenzinga•Oct 16, 2025, 12:33 PM
HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 10:42 AM
OKYO Pharma Announces Plans For Next Stage Of Clinical Development For Lead Drug Candidate, Urcosimod, To Treat Neuropathic Corneal Pain
📈 PositiveBenzinga•Sep 22, 2025, 12:37 PM
Frequently Asked Questions about OKYO
What is OKYO's current stock price?
OKYO Pharma Limited (OKYO) is currently trading at $2.03 per share. The stock has moved +8.56% today.
What is the analyst price target for OKYO?
No analyst price targets are currently available for this stock.
What sector is OKYO Pharma Limited in?
OKYO Pharma Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OKYO's market cap?
OKYO Pharma Limited has a market capitalization of $0.08 billion, making it a small-cap company.
Does OKYO pay dividends?
No, OKYO Pharma Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$2.17
Mkt Cap: $0.1B
CLNN
Clene Inc.
$6.68
Mkt Cap: $0.1B
COYA
Coya Therapeutics, Inc.
$5.49
Mkt Cap: $0.1B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
MGNX
MacroGenics, Inc.
$1.50
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
SLGL
Sol-Gel Technologies Ltd.
$42.16
Mkt Cap: $0.1B
TLSA
Tiziana Life Sciences Ltd
$1.52
Mkt Cap: $0.1B
WHWK
Whitehawk Therapeutics Inc
$2.56
Mkt Cap: $0.1B
ZNTL
Zentalis Pharmaceuticals, Inc.
$1.40
Mkt Cap: $0.1B
Explore stocks similar to OKYO for comparison